This article is part of the supplement: Proceedings of the 11th European Congress on Telepathology and 5th International Congress on Virtual Microscopy
Is HER2 amplification predictable by digital immunohistochemistry?
1 Ist Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
2 3DHistech Ltd., Budapest, Hungary
3 H-1063 Budapest, Podmaniczky u. 63, Hungary
Diagnostic Pathology 2013, 8(Suppl 1):S14 doi:10.1186/1746-1596-8-S1-S14Published: 30 September 2013
First paragraph (this article has no abstract)
In the last decade anti-HER2 treatment became one of the best examples for targeted treatment. Since the aggressive behavior of HER2-positive breast cancers could have been successfully reduced by trastuzumab therapy, HER2 positive breast cancers recently show improving prognosis. According to a four-tiered classification of international clinical guidelines, cases with strong and complete staining (IHC 3+) with anti-HER2 antibodies are eligible for trastuzumab therapy. The cases with complete, but moderate anti-HER2 stainings (2+ or equivocal) should be further investigated with (F)ISH-technique to determine HER2-amplification . Negative and IHC 3+ cases are easy to interpret semi-quantitatively on routine immunohistology, it is hard to conclude on the equivocal cases, sill, anti-HER2 therapy is indicated upon the predictive pathology report of HER2-expression and interobserver variability of IHC-interpretation still remains rather high . Furthermore, the response rate of patients to the rather expensive tratuzumab therapy that might be accompanied by side effects is still only about 50% . The rapidly developing digital pathology solutions have promised better ways of archiving, documenting and standardizing immunohistochemistry including image analysis of HER2 detection to improve the efficacy of targeted anti-HER2 therapy .